Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma

Nozomi Niitsu; Masataka Okamoto; Hirokazu Nakamine; Masami Hirano

doi:10.1016/j.leukres.2008.04.005

Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma

Nozomi Niitsu, Masataka Okamoto, Hirokazu Nakamine, Masami Hirano

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.

Original language	English
Pages (from-to)	1837-1841
Number of pages	5
Journal	Leukemia Research
Volume	32
Issue number	12
DOIs	https://doi.org/10.1016/j.leukres.2008.04.005
Publication status	Published - 12-2008
Externally published	Yes

All Science Journal Classification (ASJC) codes

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2008.04.005

Cite this

@article{92d22cef1a954dcf9b52697fef5da411,

title = "Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma",

abstract = "We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.",

author = "Nozomi Niitsu and Masataka Okamoto and Hirokazu Nakamine and Masami Hirano",

note = "Funding Information: The authors thank for having had Dr. S. Nakamura, Dr. Oshima, Dr. Tamaru, Dr. N. Nakamura and Dr. Yoshino performing pathological diagnosis. Supported in part by a grant from the Ministry of Health and Welfare, and Grants-in-Aid for Scientific Research (C) and Cancer Research, from The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) Japan.",

year = "2008",

month = dec,

doi = "10.1016/j.leukres.2008.04.005",

language = "English",

volume = "32",

pages = "1837--1841",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "12",

}

TY - JOUR

T1 - Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma

AU - Niitsu, Nozomi

AU - Okamoto, Masataka

AU - Nakamine, Hirokazu

AU - Hirano, Masami

N1 - Funding Information: The authors thank for having had Dr. S. Nakamura, Dr. Oshima, Dr. Tamaru, Dr. N. Nakamura and Dr. Yoshino performing pathological diagnosis. Supported in part by a grant from the Ministry of Health and Welfare, and Grants-in-Aid for Scientific Research (C) and Cancer Research, from The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) Japan.

PY - 2008/12

Y1 - 2008/12

N2 - We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.

AB - We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.

UR - http://www.scopus.com/inward/record.url?scp=51649089821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649089821&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2008.04.005

DO - 10.1016/j.leukres.2008.04.005

M3 - Article

C2 - 18490056

AN - SCOPUS:51649089821

SN - 0145-2126

VL - 32

SP - 1837

EP - 1841

JO - Leukemia Research

JF - Leukemia Research

IS - 12

ER -

Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this